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                                                 To my family 
ABSTRACT 
Dendritic cells (DCs) are one of the first cells to encounter HIV-1 during sexual 
transmission. They may transmit the virus to CD4+ T-cells either locally or in the 
draining lymph nodes. In the present work, we have focused the studies on monocyte 
derived DCs. Upon DC maturation, HIV-1 replication is restricted in these DCs. DC 
maturation can be triggered by pathogens, danger signals and pro-inflammatory 
mediators such as TNF-α and IFN-α. The maturation signal results in several 
functional and phenotypic changes in the DCs.  In this thesis, we have studied the 
influence of apoptotic cells and pro-inflammatory cytokines in their capacity to 
induce DC maturation and inhibit HIV-1 replication. We found that antiviral host 
APOBEC3 molecules were restricting HIV-1 replication in the DCs. We, 
furthermore, studied the effect of proteasome inhibitors on HIV-1 replication in 
primary cells. 
 
We demonstrated that apoptotic activated CD4+ T-cells (ApoAct) can trigger DC 
maturation, which was quantified in terms of expression of co-stimulatory molecules. 
In addition, we detected a reduced frequency of HIV-1 infection in DCs. A 
prerequisite, for inducing DC maturation and inhibition of HIV-1 replication by the 
apoptotic cells, was the activation of CD4+ T-cells before inducing apoptosis. Hence, 
apoptotic resting CD4+ T-cells (ApoRest) did not exert these effects on the DCs. We 
also found that DCs exposed to ApoAct (either HIV-1 infected or uninfected) 
secreted MIP-1α, MIP-1β, MCP-1, and TNF-α. Blocking of TNF-α using monoclonal 
antibodies, partially abrogated induction of co-stimulatory CD86 molecules and 
reduction of HIV-1 infection in DCs co-cultured with ApoAct. Expression of 
APOBEC3G in DCs was increased after co-culture with ApoAct, but not ApoRest. 
Silencing of APOBEC3G in DCs abrogated the HIV-1 inhibitory effect mediated by 
ApoAct. Sequence analyses of an env region revealed significant induction of G-to-A 
hypermutations in the context of GG or GA dinucleotides in DNA isolated from 
DCs/ApoAct co-cultures exposed to HIV-1, which are signs of functional APOBEC3 
activities. 
 
We found that both the cellular and supernatant fractions of apoptotic activated 
peripheral blood mononuclear cells (PBMC) were involved in triggering DC 
maturation. More specifically, the TNF-α present in the supernatant was involved and 
the cell-cell contact dependent signaling engaged beta-2 integrins, DC-SIGN and 
TLR4. We also found multiple signaling pathways and transcription factors being 
activated in DCs when they were co-cultured with ApoAct. These molecules include 
p38, JNK, PI3K-Akt, Src family of tyrosine kinases, NFκB p65 and AP1 transcription 
factor family members, c-Jun and c-Fos.  
 
We showed that DCs upon treatment with TNF-α up-regulated co-stimulatory 
molecules and were able to restrict HIV-1 replication in DCs without inducing the 
expression of APOBEC3 mRNA (A3G, A3A or A3F). However, when the DCs were 
treated with low quantities of IFN-α2b they failed to up-regulate co-stimulatory 
molecules but significantly induced A3G, A3A and A3F mRNA expression and 
restricted viral replication in DCs. Sequence analyses of the env region from HIV-1 
infected DCs treated with low quantities of IFN-α2b, showed an induction of high 
frequency of G-to-A hypermutations.  
 
 
In addition, we also demonstrated that proteasome inhibitors can effectively reduce 
transcription from the HIV-1 LTR-promoter. Treatment of PBMCs with proteasome 
inhibitors showed reduced replication of HIV-1 in PBMC. The results were similar 
when the PBMCs were treated with proteasome inhibitors alone or in combination 
with other antiretroviral drugs. Futhermore, proteasome inhibitors reduced expression 
of IL-2 inducible T-cell kinase (Itk), a Tec-family kinase that is involved in HIV-1 
replication. 
 
In conclusion, we have showed that activated apoptotic lymphocytes and pro-
inflammatory mediators can induce maturation in DCs and reduce HIV-1 infection, at 
least in part by inducing APOBEC3 molecules. Low quantities of IFN-α2b restricted 
HIV-1 replication in DCs while keeping an immature phenotype. We also identified 
some of the molecules and signaling pathways involved in DC response to ApoAct. 
Finally, proteasome inhibitors inhibit HIV-1 replication in PBMCs by targeting host 
factors essential for HIV-1 replication. These finding can be employed in therapeutic 
and/or prevention strategies.    
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1 INTRODUCTION  
1.1 HIV-1 
Since its discovery, HIV-1 infection has caused approximately 25 million deaths 
worldwide (www.unaids.org). Today very efficient antiretroviral therapy that can keep 
the viral load under detection level is available, although there is not yet a solution for 
an absolute cure or a preventive vaccine for HIV-1 infection. However, therapy is not 
always accessible to everyone. In the third world, where the majority of infected people 
live, therapy is lacking due to high cost and poor infrastructure. Several efforts with 
innovative strategies are being pursued to curb HIV-1 infection. These efforts have 
contributed to progressively turn HIV-1 infection from an inevitably fatal condition 
into a chronic manageable disease. In this thesis, attempts were made to inhibit viral 
replication in primary cells by modulating host factors. 	  
 
  
1.1.1 HIV-1 discovery 
HIV-1, the causative agent of AIDS, was discovered two and a half year [1] after this 
disease was first identified [2]. It took not more than two years for blood tests to 
become commercially available, reducing the transmission of AIDS through blood 
transfusion in developed countries to almost to zero. It was the work of two groups 
that let to the discovery of HIV-1, Robert C. Gallo in the US, Luc Montagnier and 
Françoise Barré-Sinoussi in France, were trying to isolate retroviruses from cancer 
cells. When these groups came across the medical reports of a novel immunodeficiency 
syndrome in 1981[2], the search for a causative agent was on. Both groups were 
convinced that a human retrovirus was the causative agent. In 1983, Françoise Barré-
Sinoussi and Luc Montagnier reported the first true isolate of HIV-1 from a patient 
with lymphadenopathy [1, 3]. Later in the same year, Robert Gallo at the national 
cancer institute in the US also isolated HIV-1 [4]. The progress made from the 
discovery of the virus to providing treatment for AIDS was the fastest in the medical 
history. 
 
Despite the fast development of efficient, there is still no cure or effective vaccine 
available, although significant progress has been made in understanding the viral 
transmission and pathogenesis. HIV-1 still remains a challenge for the scientific 
community. According to the UNAIDS report from 2010 an estimated 25 million 




1.1.2 HIV-1 genes and proteins 
HIV-1 is a lentivirus belonging to the Retroviridae family. It has two copies of single 
stranded RNA that consists of 9 genes that encodes 15 different proteins [5]. The HIV-1 
genome encodes the major structural and non-structural proteins common to all 
replication-competent retroviruses. From the 5'- to 3'-end of the genome is the gag 
(group-specific antigen), pol (polymerase), and env (envelope glycoprotein) genes. The 
gag gene encodes a polyprotein precursor Pr55Gag, which is cleaved by the viral 
protease to generate Gag proteins matrix (p17), capsid (p24), nucleocapsid (p7), p6 and 
two spacer peptides, p2 and p1. The Gag proteins drive the assembly and release of 
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virus particles and encapsulate the viral RNA genome. The pol-encoded enzymes are 
initially synthesized as part of a large polyprotein precursor Pr160GagPol. The Gag and 
Pol precursors are cleaved by the viral protease. The pol-encoded enzymes- protease 
involved in cleaving the viral polypeptide precursor, reverse transcriptase (RT) 
converts the viral RNA genome into double stranded DNA, and integrase catalyze the 
integration of viral DNA into the host cell chromosome.  
 
The Env precursor, known as gp160, is processed by a cellular protease during Env 
trafficking to the cell surface. gp160 processing results in the generation of gp120 the 
surface Env glycoprotein and gp41 the transmembrane glycoprotein. gp120 interacts 
with receptor and co-receptor, and gp41 anchors the gp120/gp41 complex in the 
membrane and also contains domains that are critical for catalyzing the membrane 
fusion reaction between viral and host lipid bilayers during virus entry. In addition to 
the gag, pol, and env genes, HIV-1 also encodes a number of regulatory and accessory 
proteins. Tat is critical for transcription from the HIV-1 LTR and Rev plays a major 
role in the transport of viral RNAs from the nucleus to the cytoplasm. Vpu, Vif, Vpr 
and Nef are accessory proteins [5-7]. Vpu mediates degradation of CD4 and down 
regulation surface expression of MHC class 1 molecules [8, 9]. Nef is also involved in 
down regulation of CD4 molecules and MHC class I molecules [10, 11]. Vpr and Vif 
have implications in cytopathicity and G2 cell cycle arrest [12-14] Vif also mediates 
degradation of APOBEC3G molecules through the ubiquitin proteasome pathway [15].   
 
 
1.1.3    HIV-1 Replication cycle  
The HIV-1 replication cycle can be divided into an early and a late phase. In the early 
events, the virus binds to its main receptor CD4, expressed primarily on the cell 
surface of T-cells and macrophages, as well as a co-receptor [5]. In dendritic cells, 
HIV-1 gp120 binds to the C-type lectin DC-SIGN [16]. The main co-receptors are the 
chemokine receptors CCR5 and CXCR4. After the binding, the virus uses the host 
cholesterol rich lipid rafts for the membrane fusion between the lipid bilayers of the 
viral envelope and the host cell plasma membrane. Upon entry into the host 
cytoplasm, the viral RT facilities the reverse transcription of the viral RNA into 
DNA. The DNA is subsequently imported into the nucleus as preintegration complex. 
Viral DNA integrates into the host cell chromosome and the reaction is catalyzed by 
the viral integrase. The late events include the expression of the provirus, transport of 
the viral mRNA to the cytoplasm by Rev and assembly and budding with the aid of the 
Gag protein.  
 
1.1.3.1 Entry and membrane fusion 
 
The CD4 molecule is the principal HIV-1 receptor [17]. A small segment of the N-
terminal extracellular domain of CD4 has a high-affinity for binding to gp120. There 
are five conserved domains (C1-C5) and five variable domains (V1-V5) in gp120. 
CD4 binding site in gp120 is deeply recessed and flanked by heavily glycosylated 
variable regions [18].  
 
CD4 alone is not sufficient for HIV-1 Env-mediated membrane fusion and virus 
entry. This conclusion came from the observation that primary virus isolates from 
HIV-1 infected individuals display variable tropism for CD4+ T-cells. Certain 
isolates, referred to as macrophage-tropic replicated efficiently in primary 
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macrophage cultures, whereas other isolates, referred to as T-cell-line tropic did not 
productively infect macrophages but replicated efficiently in T-cell lines. Both 
isolates replicated in activated peripheral blood mononuclear cells (PBMC). Members 
of the G protein-coupled receptor superfamily of seven-transmembrane domain 
proteins act as a co-receptors for HIV-1 entry [19, 20]. These molecules are receptors 
for the α- and β-chemokines. The two most important co-receptors are the α-
chemokine receptor CXCR4 and the β-chemokine receptor CCR5. The viral strains 
are named based on the co-receptor usage, the strains that preferentially use CXCR4 
are named as X4 viruses and the strains that utilized CCR5 are termed as R5 viruses, 




The V3 loop of gp120 plays a major role in determining HIV-1 tropism, exchanging 
the V3 region between isolates can confer macrophage tropism upon T-cell line-tropic 
clones [21]. The V1/V2 region also appears to influence co-receptor usage. In addition 
to the V1/V2 and V3 variable loops, highly conserved regions of gp120 take part in 
co-receptor binding. The binding of gp120 to CD4 changes the conformation of gp120 
so that its affinity for co-receptor is increased. gp120 first binds CD4 to form a 
complex composed of gp120, CD4, and co-receptor and then there is a conformational 
change in gp41, which triggers membrane fusion [19-21]. The importance of co-
receptors in vivo were shown by a number of studies indicating that genetic 
heterogeneity at co-receptor alleles can affect the susceptibility of an individual to 
HIV-1 infection. The best characterized example of this phenomenon is the 
CCR5/Δ32 mutation. The individuals homozygous for this mutant allele encodes for a 
truncated form of the CCR5 protein are almost completely resistant to HIV-1 infection 
[22-24].  
 
The membrane fusion that takes place between the lipid bilayers of the viral envelope 
and the host cell plasma membrane enables the viral core to gain access to the 
cytoplasm. The membrane fusion is catalyzed by the gp120/gp41 Env glycoprotein 
complex. The gp41 contains a highly hydrophobic N-terminus also known as the 
fusion peptide and two motifs N-helix and the C-helix. These helixes are organized in 
an antiparallel fashion to generate a six-helix bundle [25, 26]. Mutations in these 
helixes can inhibit membrane fusion and the helixes also undergo rearrangements 
following CD4/co-receptor binding to ensure that the N-terminal fusion peptide inserts 
directly into the target membrane.  
 
 
1.1.3.2 Reverse transcription and integration 
  
Reverse transcription is initiated using a tRNA molecule that is bound to the primer 
binding site [27, 28]. DNA synthesis proceeds to the 5' end of the RNA molecule, 
generating a DNA/RNA hybrid. The RNA portion of this hybrid is degraded by the 
RNaseH, which is part of the RT holoenzyme, leading to the generation a DNA 
fragment known as the minus-strand strong stop DNA. The minus-strand strong stop 
DNA has short regions of homology called the R regions. Using these R regions the 
minus-strand strong stop DNA jumps from the 5' to the 3' end of the genome. This 
step is referred as the first strand transfer. Minus-strand synthesis occurs by using the 
3' end of the minus-strand strong stop DNA as a primer. The RNA remaining from 
minus-strand synthesis acts as a primer for plus-strand synthesis. The priming occurs 
at a purine rich sequence known as the central polypurine tract. The tRNA bound to 
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the primer binding site is removed by RNaseH, thereby allowing second-strand 
transfer to take place. Plus-strand synthesis proceeds to the end of the minus strand. 
An additional termination site, referred to as the central termination signal, is located 
near the center of the genome. Since the CTS are 3' of the central polypurine tract, 
approximately 100 nucleotides of plus-strand DNA is displaced which results in the 
formation of a DNA flap. It has been reported that this central flap plays a crucial role 
in the import of the viral preintegration complex to the nucleus [29, 30].  
 
The RT/template interaction is of a relatively low affinity because reverse 
transcription involves “jumps” from one template to another [31]. As a consequence 
of frequent template switch, novel recombinant DNA genome containing sequences 
derived from both parental RNAs are generated [32]. The high frequency of genetic 
recombination, together with the high mutation rate of HIV-1 RT (3 x 10-5 per cycle of 
replication)[33] results in HIV-1 populations being highly heterogeneous in sequence 
forming quasi-species. This gives HIV-1 an upper hand in rapidly evading the host 
immune response and developing resistance to antiviral drugs. 
 
The viral DNA is transported to the nucleus as part of the preintegration complex. 
The viral integrase protein catalyzes the insertion of the linear, double-stranded viral 
DNA into the host cell chromosome. The integrated DNA, which is referred to as the 
provirus, behaves essentially as a cellular gene. Integration is an essential step in 
retrovirus replication. An integrase mutant generally fails to establish spreading 
infections. The integrase clips off several nucleotides from the 3’ termini of both 
strands of linear viral DNA. This reaction is known as 3'-end processing and 
generates a double-stranded DNA with 3’-recessed ends. In the nucleus, integrase 
makes a staggered cleavage in the cellular target DNA. The 3’recessed ends of viral 
DNA formed in the 3'-end processing reaction are joined to the ends of the cleaved 
cellular DNA by a process known as strand transfer. Cellular repair enzymes fill in 
the gaps between the integrated viral DNA and the host target DNA to complete the 
integration process [7]. 
 
1.1.3.3 Provirus expression and budding  
 
New viruses are made from the provirus that has been integrated into the host genome. 
The provirus makes use of host cellular machineries to produce new viruses. 
Transcription of HIV-1 is initiated at LTR (Long Terminal Repeat), which has cis-
acting elements required for RNA synthesis [5]. The HIV-1 LTR has three regions - 
U3, R and U5. Transcription is initiated at the U3/R junction. U3 contains the 
required elements that direct the binding of RNA polymerase II to the DNA template. 
The transcription factor II D binds to the TATA box that is located approximately 25 
nucleotides upstream of the transcription start site. There are three Sp1 and two NF-
κB binding sites at the 5' of the TATA box. There is a modulatory region upstream of 
the NF-κB sites, which contains binding sites for several additional transcriptional 
factors. The basal transcriptional activity from the HIV-1 LTR is very low but the 
RNA synthesis is greatly increased when the viral protein transcriptional 
transactivator protein Tat is present [34, 35]. Tat stimulates transcription of HIV-1 by 
interacting with a stem-loop structure known as the transactivation response element 
(TAR) [36]. Tat do not act alone, it directly interacts with a host cell factor cyclin T, 
which in turn recruits a cyclin-dependent kinase (CDK9) to the TAR element [37]. 
Cyclin T and CDK9 form a complex known as positive transcription elongation 
factor b (P-TEF-b). This results in hyper-phosphorylation of the RNA polymerase II, 
which in turn stimulates transcriptional elongation. HIV-1 structural proteins are 
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encoded by unspliced or partially spliced mRNAs and the viral RNA genome itself is 
derived from a full-length RNA. The unspliced mRNA cannot be exported to the 
cytoplasm and HIV-1 uses the viral protein Rev to overcome this problem. Rev binds 
to a cis-acting RNA element known as the Rev-response element (RRE) to facilitate 
the export of unspliced or partially spliced mRNA to the cytoplasm [38]. Rev uses the 
cellular machinery to shuttle back and forth to the nucleus. It binds to the cellular 
nuclear import receptor importin b to enter the nucleus. To export the RNA to the 
cytoplasm, Rev interacts with the nucleocytoplasmic transport factor Crm1 [39]. 
Once all the necessary proteins are made, the new virion is packed with two copies of 
single stranded RNA in the cytoplasm and budded out. Lipid rafts are involved in 
budding of the virus [40-42]. The p6 domain of Gag plays an important role in 







Figure 1. HIV-1 replication cycle (1) The early phase begins with viral attachment, quickly 
followed by fusion and entry (2) Uncoating of the viral core (3) Reverse transcription converts 
the single-stranded viral RNA genome into double-stranded DNA (4) The preintegration 
complex of viral and cellular proteins is transported to the nucleus (5) Integration of viral DNA 
into the host chromosomal DNA. (6) Late phase of the cycle, Initiation of transcription by RNA 
Pol II generates spliced and unspliced mRNA templates. (7) Translation produces accessory 
proteins and polyproteins (Gag and Gag-Pol) encoding structural and enzymatic proteins (8) 
Core particle assembly is initiated and (9) Final assembly and release of progeny virions. Figure 
adapted from [5]. 
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1.1.4 NF-κB 
NF-κB is a ubiquitous transcription factor and has five members, NF-κB1 (p50), NF-
κB2 (p52), RelA (p65), c-RelA and RelB. In a steady state condition, NF-κB stays in 
the cytosol as heterodimers (p65/RelA, p50/NF-κB1). NF-κB is maintained as a 
heterodimer by an inhibitory protein IκB [45]. Following cellular stimulation, these 
inhibitory proteins are phosphorylated and subsequently degraded by the ubiquitin-
proteasome pathway (UPP) leading to the release of NF-κB. Free NF-κB translocates 
to the nucleus and binding to the NF-κB binding site of the viral LTR and initiates 
provirus transcription [46, 47]. NF-κB activation and signalling is known to be strictly 
dependent on the activity of the 26S proteasome [48, 49].  
 
 
1.1.5 HIV-1 transmission and pathogenesis  
Most of the HIV-1 infections occur after HIV-1 exposure on a mucosal surface. The 
infection risk varies according to the route of infection [50] and there are many factors 
associated with mucosal integrity. In addition, genetic constitution influences the 
susceptibility and resistance to HIV-1 infection during sexual transmission [51]. The 
knowledge of initial events of HIV-1 infection are obtained by studying the human 
tissue explants [52, 53] and vaginal inoculation of macaque with SIV [54-57]. These 
studies suggest that CD4+ T-cells and dendritic Langerhans cells are the first targets in 
HIV-1 infection [52, 53]. In addition, other DC populations may also play an important 
role [58]. The virus crosses the mucosal barrier by transcytosis - a vesicular transport 
from one side of the cell to another or through intercellular space in the epithelium or 
by binding to the DCs in the intraepithelial to access the target cells [59]. Viral 
evolution studies on viruses present early after viral transmission have shown that HIV-
1 infection often occurs from a single founder virus [60, 61]. 
 
During vaginal transmission, the virus can be transported from the mucosa to the 
draining lymph node by the DCs where the virus infects CD4+ CCR5+ T-cells [16]. 
Studies using SIV-infected rhesus macaque (both intrarectal and intravenous 
inoculation) has shown that primary infection is characterized by a selective loss of 
CD4+ T-cells within mucosa-associated lymphoid tissues that coincides with the 
massive increase of viral load in the plasma [62-64]. In the intravenously SIV-
infected rhesus macaque, depletion of GALT CD4+ T-cells occurs relatively rapidly 
within 1–2 weeks post-infection and mainly at effector sites, i.e., the lamina propria 
[65]. Recent studies have provided evidence that this massive mucosal CD4+ T-cell 
depletion is not a specific characteristic of the SIV-macaque model, but is also 
observed in the gut of acutely HIV-1-infected patients 4–6 weeks post infection [66-
68]. The SIV-macaque model with different route of inoculation reveals that this trait 
is independent of the route of transmission [57, 69-72]. High levels of CCR5 and 
CXCR4 co-receptor expression on intestinal CD4+ T-cells, and their predominantly 
activated state make them highly susceptible to the viral infection and this may, in 
part, explain the severity of CD4+ T-cell depletion seen in GALT [73]. When HIV-1 
vigorously replicates in the GALT and other lymphoid tissues, the viral load in the 
plasma increases exponentially to reach a peak, usually more than a million RNA 
copies per ml of blood, but the CD4+ T-cell decreases in number and later returns to 
near normal levels in the blood but not in the GALT [64, 66, 74]. After the acute 
phase of infection there is an asymptomatic period of HIV-1 infection were the viral 
load decreases to reach a more stable level, known as the viral set point. This viral set 
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point is believed to occur when there is equilibrium between viral replication and 
immune control [75-77].  
 
Knowledge on HIV-1 life cycle has not only enabled the discovery of antiretroviral 
drugs but may also pave the way for better understanding of the host factors involved 
in the viral life cycle that can be novel targets for inhibiting viral replication. 
 
 
1.2 Host restriction factors – A defence against HIV-1 infection 
Humans and other mammals have developed a system of antiviral activities mediated 
by intracellular proteins referred to as restriction factors. These proteins can block 
infection of sensitive viruses after they have entered the host cell. They are species 
specific in that each species can restrict a subset of viruses with exquisite sensitivity 
[78]. TRIM5α, tetherin and APOBEC3 molecules and recently dendritic and myeloid 
cell specific restriction factor called SAMHD1 were all identified to have antiviral 
activity. In recent studies, human genes were screened for identification of HIV-1 
restriction factors and factors involved in HIV-1 replication using siRNA genomic 
screens. These studies revealed numerous genes involved in restriction of HIV-1 
replication during the early stages of the viral life cycle [79-83]. However, these 
studies did not always reveal the same target genes. This may be due to the fact that 
different cellular targets were used, different viral strains grown in different target 
cells in vitro or the use of pseudoviruses, differences in kinetics, doses of viruses 
used, to mention some factors that can explain the differential outcome. Hence, a lot 
of work remains to be done to validate the target genes discovered in the siRNA 
genomic screens. Here short descriptions are made for the so far most studied HIV-1 
restriction molecules. 
 
1.2.1 TRIM5α  
Tripartite motif-containing protein 5 or TRIM5α mediates low level of HIV-1 
replication inhibition in humans, but they play a very important role in the antiviral 
activity in non-human primates [84]. TRIM5α binds as multimer to the incoming virus 
capsid, which leads to a premature uncoating of the capsid thereby restricting reverse 
transcription and nuclear transport of the viral genome [85, 86]. The exact mechanism 
of action of TRIM5α, has not been shown conclusively, but the capsid protein from 
restricted viruses, is ultimately removed by proteasome-dependent degradation [87]. 
 
1.2.2 Tetherin  
Tetherin is another human cellular protein, which contributes to retroviral inhibition 
[88]. Tetherin is also known as bone marrow stromal antigen 2 or CD317. Tetherin is a 
type 2 integral membrane protein. When the virus buds from the surface of the cell, 
tetherin tethers the virions to the producer cell, by means of its N-terminal 
transmembrane domain and its C-terminal glycosyl-phosphatidylinositol anchor there 
by inhibits the release of the virus from the producer cell. The viral protein Vpu 
antagonizes tetherin [88]. Tetherin also cross-links the virions to each other resulting in 
the inhibition of the release of the virus from the infected cell. 
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1.2.3 SAMHD1 
The cell specific SAM domain HD domain-containing protein 1 or SAMHD1 is a 
protein involved in Aicardi–Goutieres syndrome, a genetic encephalopathy with 
symptoms mimicking congenital viral infection. SAMHD1 negatively regulates 
interferon responses [89]. A recent study has shown that SAMHD1 acts as an 
antiretroviral factor [90]. The quantification of total viral DNA species after infection 
in SAMHD1 silenced cells resulted in the accumulation of total viral DNA shows that 
the restriction is at the reverse transcription level. The report concludes that 
SAMHD1 is expressed in cells of the myeloid lineage and inhibits viral replication by 
interfering at an early step of the viral life cycle. Viral protein Vpx counter acts 
SAMHD1 by inducing proteasomal degradation [90, 91]. 
 
1.2.4 Zinc-finger antiviral protein (ZAP) 
A recent report have demonstrated that ZAP inhibits HIV-1 by recruiting both the 5’ 
and 3’ mRNA degradation machinery to specifically promote the degradation of 
multiply spliced HIV-1 mRNAs. ZAP selectively recruits cellular poly(A)-specific 
ribonuclease (PARN) to shorten the poly(A) tail of target viral mRNA and recruits 
the RNA exosome to degrade the RNA body from the 3’ end. In addition, ZAP 
recruits cellular decapping complex through its cofactor RNA helicase p72 to initiate 
degradation of the target viral mRNA from the 5’ end. Depletion of each of these 
mRNA degradation enzymes reduced ZAP’s activity [92].  
 
1.2.5 APOBEC3 molecules 
APOBEC3 proteins or apolipoprotein B mRNA-editing enzyme 3 belongs to cellular 
polynucleotide cytidine deaminases family. Initially, Vif was considered to be 
important for the production of infectious virus from the proviral genome [93, 94]. The 
APOBEC3G antiretroviral factor was initially named CEM15. CEM-SS is a T-cell 
line that supports replication of Δvif virus. When these cells, were stably transduced 
with CEM15 encoding retroviral vector that enforced expression of APOBEC3G 
(CEM15), these cells restricted the replication of Δvif virus. With this experiment it 
was demonstrated that APOBEC3G is a restriction factor and was responsible for 
restricting HIV-1 infection [15].  
 
Six members of APOBEC3 family have been identified to be involved in HIV-1 
restriction. Studies on APOBEC3G (A3G) have shed lights on the molecular 
mechanism by which the APOBEC3 family member act on the virus and how viral 
Vif counteracts them. A3G has a DNA deaminase activity with distinct sequence 
specificity [95]. A3G molecules have to be present in the virus producing cells to 
exert antiviral function. To do so, A3G molecules get packaged into viral particles 
and when the virus enters a fresh cell A3G heavily deaminate cytosines into uracils in 
minus-strand viral DNA during the viral reverse transcription [96-100]. Adenine is 
incorporated on the opposite plus-strand as a result of uracil introduction in the 
minus-strand viral DNA. The deaminase activity on the minus-strand can be deduced 
by the accumulation of G-to-A hypermutations mainly on the plus-strand viral DNA 
following second-strand synthesis. The frequent detection of G-to-A hypermutation 
in samples from HIV-1 patients constitutes clear evidence that A3G does act to 
deaminate the HIV-1 DNA during natural infection [101, 102]. These hypermutations 
can be lethal to the virus in two ways. First, the G-to-A hypermutation would get 
fixed in the provirus, which leads to truncated protein production or disturbed viral 
  9 
gene expression. Second, uracil residues can be recognized by cellular DNA repair 
enzymes, leading to the degradation of the unpaired DNA strands as a part of repair 
mechanism [103] (Fig.2).  
 
A study showed that in resting CD4+ T-cells, A3G exists predominantly in the low 
molecular mass (LMM) configuration and was shown to impose a potent post-entry 
restriction on HIV-1infection [104]. But this report was later retracted, as another 
study failed to confirm the above mentioned claim about involvement of A3G in the 
post-entry restriction of HIV-1 [105]. Thus, the relative contribution of A3G to the 
resistance of quiescent T-cells to HIV-1 infection remains to be resolved. 
 
Apart from the cytidine deaminases activity, A3G is proposed to interfere with 
reverse transcription by inhibiting tRNA3Lys from binding to the HIV-1 primer-
binding site [106]. Removal of primer tRNA from the minus-strand results in an 
insufficient substrate for the integrase that inhibits proviral integration in the host 
genome [107].  
 
Vif counteracts APOBEC3G by recruiting E3 ubiquitin ligase complex through the 
interaction of Vif BC box motif and elongin C [108-111]. Vif acts as a bridge to 
target APOBEC3G for ubiquitination through its N-terminal domain and subsequent 
degradation of APOBEC3G via the proteasomal degradation pathway [112-115]. 
 
Apart from A3G there are other APOBEC3 members that play a role in HIV-1 
inhibition. APOBEC3F (A3F)	  is a strong inhibitor of Vif deficient HIV-1. It inhibits 
viral replication in the same fashion as A3G by introducing G-to-A mutation in the 
viral genome, though the degree of mutagenesis has been noted to be lower than A3G 
in some cell culture experiments. [116-120]. A3F also undergo Vif-mediated 
proteasomal degradation [121]. APOBEC3B (A3B) is another member of the 
APOBEC3 family, which is resistant to Vif and it has been shown to have significant 
antiviral effect but is poorly expressed in CD4+ T-cells so it may not have a 
significant effect on HIV-1 during natural infection. A3G, A3F and A3B have two 
CDA domains [116, 122, 123]. APOBEC3A (A3A) contains a single CDA domain, is 
expressed in immature monocytes and in other myeloid cells. A3A has been reported 
to restrict HIV-1 infection during the early phase of its life cycle. The antiviral effect 
of A3A is exerted at the reverse transcription step through a mechanism that may 
involve deamination. [124, 125]. APOBEC3C (A3C) also contains a single CDA 
domain, is expressed in CD4+ T-cells and can act in target cells to introduce 
infrequent G-to-A mutations at sublethal levels during infection by some HIV-1 
strains [126]. Lastly, a single domain protein, APOBEC3D/E (A3D/E), can also 
modestly inhibit HIV-1 infection in a Vif-sensitive manner when overexpressed in 
virus-producing cells [127]. 
 
During natural infection, the virus has an active Vif to counter act APOBEC3 and one 
can argue that Vif might mediate low effectiveness of APOBEC3 molecules, which in 
turn will result in introduction of sub lethal mutations which might add up to the viral 
genetic diversity. Population studies have shown that there is a possibility of 
variations in the functionality of different vif alleles [128], mRNA level of A3G and 
A3F are associated with infection status, as well as with differences in rates of disease 
progression, plasma virus loads, and transmission [129-131]. In addition, increased 
CD4+ T-cell counts and decreased virus loads have each been correlated with the 
hypermutated HIV-1 sequences [101, 132]. Strategies to enhance or modulate the 
expression of host restriction factors could be vital in preventing HIV-1 transmission. 
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Discovery of more restriction factor will shed light on host defense mechanism 









1.3 Dendritic cells  
Dendritic cells are sparsely distributed antigen-presenting cells (APCs), which play a 
critical role in bridging the innate and adaptive immune response. Dendritic cells 
(DCs) have been referred to as “professional” APCs. The principal function of DCs is 
to present antigens, and to induce a primary immune response in resting naive T-cell. 
To perform this function, DCs capture antigens, process them, and present them on 
the cell surface as peptides on the major histocompatibility complexes (MHC). DCs 
can also present self-antigens to T-cells to regulate T cell activation or in other words 
induce tolerance [134].  
 
DCs were first observed in human skin by Paul Langerhans in 1868 and were named 
Langerhans cells (LCs). LCs were mistaken as nerve cells due to their morphology. 
Steinman and Cohn established the term dendritic cell when they discovered these 
cells in mouse spleen [135-137]. Later LCs and DCs have proved to be originated 
from hematopoietic progenitors in the bone marrow [138].  
 
1.3.1 DC subsets  
DCs constitute a heterogeneous population of cells located throughout the blood, 
tissues, and lymphoid organs and are derived from different lineages [139]. They are 
involved in the generation of both innate and acquired immune responses, including 
release of cytokines such as IL-12, IL-10, and IFN-α, stimulation of naive T-cell 
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clonal expansion [140, 141], natural killer (NK) cell stimulation [142] and plays an 
important role in peripheral tolerance to self peptides [143]. DCs are derived from 
CD34+ stem cells via at least two generation pathways: myeloid and lymphoid [144]. 
Myeloid DCs (mDCs) also known as conventional DCs (cDC), characterized by 
CD1a and CD11c expression, are found in most tissues except the brain and testes 
[141]. DCs of lymphoid lineage, commonly called plasmacytoid DCs (pDCs), have a 
more restricted distribution being found predominantly in the blood and lymphoid 
tissues [145, 146].	   DCs can also be generated from blood monocytes (known as 
monocyte derived DCs or MDDCs) or bone marrow precursors [147, 148]. 
 
Dendritic cells express different pattern recognition receptors (PRR), depending on 
the cell subset and to some extent on location. These PRR are able to recognize 
motifs unique to different classes of pathogen [149, 150]. The PRRs includes C type 
lectin receptors (CLR), which recognize glycosylated carbohydrate domains [151] 
and Toll like receptors (TLR), which have a high degree of specificity for individual 
pathogen associated molecular patterns [152], retinoic acid-inducible gene I (RIG-I)-
like receptors (RLRs), and nucleotide-binding oligomerization domain (NOD)-like 
receptors (NLRs) [153]. 
 
1.3.2 DC maturation and migration  
DCs exist as precursors, immature and mature DCs, and their location in the body 
depends on the state of maturation. Immature DCs are very efficient in picking up 
antigens as they look for pathogens in the surrounding area, express moderate 
amounts of MHC class II and low levels of co-stimulatory molecules. They also 
express the chemokine receptors CCR1 and CCR5. DCs are matured in response to 
stimuli such as antigen uptake or viral replication in DCs as well as exogenous 
stimuli such as lipopolysaccharide (LPS) or cytokines such as TNF-α. Maturation 
results in many functional and phenotype changes in DCs. 1) Up-regulation of DC 
co-stimulatory molecules CD40, CD80, CD83, CD86, and also MHC class II are all 
up-regulated as well as adhesion molecules ICAM-1 and VLA-4, which enables more 
prolonged DC-T-cell interaction [154, 155].  2) Chemokine receptors CCR7 
expression on DCs are increased, which induces migration to the secondary lymphoid 
tissue [156] in response to CCL21 and CCL4 produced in the lymph node [157, 158]. 
3) Secretion of cytokines IL-12, IL-15, IL-18 and chemokines MDC, TARC, ELC, 
stimulates DC-T-cell interactions, which helps in helper and cytotoxic T lymphocytes 
activation [159] and 4) C-type lectin receptor DC-SIGN, mannose receptor (MR) and 
to a lesser degree, Langerin are all down-regulated by maturation. DC maturation can 
be triggered by recognition of pathogen associated molecular patters (PAMPs) that 
engage for example TLRs, NLRs, or C-type lectins expressed in DCs. DCs can also 
respond to endogenous danger associated molecular patterns (DAMPs) from injured 
cells [160]. The High mobility group box 1 (HMGB1) protein is released from necrotic 
and late apoptotic cells [161, 162]. HMGB1 has been shown to induce DC maturation 
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1.3.3 DCs during HIV-1 infection 
DCs are one of the first cells to meet HIV-1 during sexual transmission. They detect 
viruses in peripheral tissue sites and following viral uptake and activation they 
migrate to draining lymph nodes, where they trigger adaptive immune responses and 
promote NK cell activation. 
 
Reports from animal studies suggest that HIV-1 transmission by DCs can occur either 
by direct infection (cis) or through binding of the virus to DCs without infection 
(trans) [164-166]. Apart from the CD4 and chemokine receptors expressed on DCs 
HIV-1 also uses C-type lectin receptor DC-specific ICAM3-grabbing non-integrin 
(DC-SIGN), Langerin (also known as CLEC4K or CD207) and DC immunoreceptor 
(DCIR; also known as CLEC4A) to enter DCs [16, 167]. HIV-1 also uses lipid drafts 
to bind and internalize into DCs [168]. Expression of these receptors varies according 
to the DC subtype, localization and maturation status. The gp120 of HIV-1 envelope 
binds to DC-SIGN of DCs and enters early endosomal compartment where the virus 
stays intact. When the DCs reach the draining lymph nodes they promote infection to 
the T-cells through viral synapses or cell-cell fusion or other mechanisms [169]. 
There is also a report that the transfer of HIV-1 to T-cells can occur independently of 
DC-SIGN [170]. DCIR was also recently found to bind to HIV-1 and promotes 
transmission of infectious virus to CD4+ T-cells in a similar fashion to DC-SIGN 
[171]. Langerin can bind and internalize HIV-1 and migratory Langerhans cells are 
believed to enhance HIV-1 infection by promoting the spread of the virus to T-cells 
in draining lymph nodes. In-vitro-derived Langerhans cells can transmit infectious 
HIV-1 to T-cells [172]. 
 
HIV-1 does not induce maturation of cDCs by activating TLRs [173] however there 
are reports claiming that HIV-1 matures MDDCs and Langerhans cells [174]. 
Replication of integrated HIV-1 in immature cDCs can be initiated by TLR8 and DC-
SIGN mediated signal transduction events [175]. HIV-1 is targeted to TLR8 
containing endosomal compartments by DC-SIGN, and this initiates the transcription 
of integrated HIV-1 DNA through TLR8 activation and subsequent nuclear factor-κB 
(NF-κB) signaling. The binding of gp120 to DC-SIGN leads to RAF1-mediated 
phosphorylation of the p65 subunit of NF-κB, which results in productive 
transcription within infected DCs [175]. Following HIV-1 infection, fusion between 
endosomes and autophagosomes is inhibited and this prevents autophagy-mediated 
viral degradation [176]. 
 
There is a progressive reduction in blood DC numbers after HIV-1 infection that 
correlates with increasing plasma viral load and disease progression [177-180]. This 
decrease in DC frequency occurs early during acute HIV-1 infection and is sustained 
in the later stages of infection. Patients with chronic HIV-1 infection also have fewer 
blood DCs compared with uninfected controls [181, 182]. It was observed that DC 
numbers returned to normal levels following antiretroviral therapy (ART) [183]. 
 
DCs undergo several functional changes during HIV-1 infection. Their maturation is 
impaired, they have an altered cytokine profile and also altered ability to stimulate T-
cells [184, 185]. HIV-1 proteins Vpr and Nef are shown to be involved in the 
reduction of co-stimulator molecules CD80 and CD86, they are also involved in the 
reduction of HLA-DR in DCs, this in turn reduces the ability of the DCs to stimulate 
CD8+ T-cell activation [186-189]. Studies from our group has reveled that HIV-1-
infected DCs up-regulate cell surface markers but fail to produce IL-12 p70 in 
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response to CD40 ligand stimulation [190]. 
  
cDCs from patients with acute HIV-1 infection produce increased levels of IL-12p70, 
IL-6, TNF-α and MIP-1α compared with cDCs from uninfected controls [181]. pDCs 
isolated from patients with acute HIV-1 infection has shown decreased IFN-α 
production during the early stages of infection, but increased IFN-α production at 
later stages of infection [181]. Although IFN-α produced by pDCs can inhibit viral 
replication they do not inhibit transmission of the virus to CD4+ T-cells [191]. The 
altered cytokine production and down regulation of co-stimulatory molecules, MHC 
class I and CD4 of DCs by HIV-1 could explain, at least in part, the severe 
impairment of T-cell function during HIV-1 infection [192]. Upregulation of DC-
SIGN can favor the transmission of the virus to the CD4+ T-cells through DC-T cell 
contact. The close interaction of CD4+ T-cells with APCs has been shown to favor 
HIV-1 replication [193] this can be the reason why HIV-1 specific memory CD4+ T-
cells are readily infected compared to memory CD4+ T-cells with other specificities 
[194]. DC when co-cultured with activated CD4+ T-cells enhances viral replication in 
a cell-cell contact dependent manner [195]. 
 
Although HIV-1 can induce DC dysfunction, the DCs are capable of initiating 
effective T-cell response during acute and early infection [196]. These DCs are likely 
to be uninfected and prime T-cells by cross-presentation or by direct presentation of 
exogenously derived viral antigen that are derived from non-infectious virus or from 
previously infected apoptotic cells or from immune complexes. The cross-
presentation of HIV-1 antigen derived from apoptotic cells has been shown to induce 
both CD4+ and CD8+ memory T-cell response [197, 198]. Cross-presentation of 
infected apoptotic cells has been shown to be more effective than the direct 
presentation of non-infectious virus or infectious virus [199].  
 
DCs are being investigated as candidates for immunotherapeutic strategies to 
augment T-cell immunity to HIV-1 infection, but more work has to be done to get a 




Apoptosis and necrosis are two major processes by which cells die. During necrosis, 
the cell ruptures and releases its intracellular content, which activates macrophages 
leading to the release of pro-inflammatory cytokines. These cytokines may provide the 
co-stimulation required for T-cell activation and immunity. Apoptosis is a controlled 
process, in organogenesis and tissue remodelling during development, to eliminate 
used-up, damaged, or misplaced cells during the embryonic development and the tissue 
homeostasis of multicellular organisms. Apoptotic cell death also occurs during 
infections and wound healing and in different disease states [200, 201].  
 
There are many stimuli and conditions, both physiological and pathological, which can 
trigger apoptosis. It is an energy-dependent process, which implicates the activation of 
a group of cysteine proteases called caspases in a complex cascade of events [202-204]. 
Depending on the initiating stimuli, two major mechanisms could be defined: the 
intrinsic pathway or mitochondrial pathway [205], that involves members of the bcl-2 
family and mitochondrial functions and the extrinsic pathway which is activated by 
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extracellular signals that act via death receptors (DR) [206, 207]. Several DRs have 
been described that all belong to the TNF receptor superfamily. Each pathway activates 
its own initiator caspase, which, in turn, will activate the executioner caspase-3. There 
are evidences that the two pathways are linked and that molecules in one pathway can 
influence the other [208]. A third pathway, involving T-cell mediated cytotoxicity and 
perforin/granzyme dependent killing of cell works in a caspase-independent fashion.  
 
 
1.4.1 Uptake of apoptotic cells by phagocytes 
DCs can take up pathogens as well as apoptotic cells. The ingestion of pathogens often 
triggers a pro-inflammatory response, whereas the engulfment of apoptotic cells is 
generally anti-inflammatory or immunologically silent [209]. The recognition of 
apoptotic cells involves the 'eat-me' signals that they display on the cell surface, and 
many of these signals are recognized by engulfment receptors that are expressed by the 
phagocyte [210]. Uptake of apoptotic bodies involve sensing, recognition of the 
apoptotic cells by the DCs, cytoskeletal reorganization and internalization of the target, 
processing and degradation of the ingested apoptotic cell and post-engulfment 
responses of the DCs.  
 
Sensing of apoptotic bodies by phagocytes can be promoted by the “find me” signal 
molecules like lysophosphatidylcholine (LPC) [211] and nucleotides such as ATP and 
UTP [212]. These molecules, which are diffusible extracellular factors, promote the 
recruitment of phagocytes. The molecules that are involved in the “eat me” signal are 
found in the surface of the apoptotic cell. Phosphatidylserine is one such molecule that 
is found on the plasma membrane of the apoptotic cell. Other eat-me signals include 
changes in the surface charge of glycoproteins and lipids resulting in addition of sugars, 
the binding of thrombospondin or the complement component C1q to the apoptotic-cell 
surface, and the expression of intercellular adhesion molecule 3 (ICAM3) and oxidized 
low-density lipoprotein (LDL)-like moiety [213-216]. 
 
There are several receptors expressed by the phagocyte that recognize these eat-me 
signals. Lectins that bind altered sugars [217], the vitronectin receptor that binds 
thrombospondin [218], scavenger receptors that bind oxidized LDL-like moieties [219], 
CD14 that binds ICAM3 [220], CD91 also known as LRP1 binds C1q through 
calreticulin [221] [222] and the receptor tyrosine kinase MER binds to the serum-
derived protein GAS6 growth-arrest-specific 6 [223]. Apoptotic cell recognition 
appears to depend on the cell that is being engulfed, the receptors that are expressed by 
the phagocyte and the state of activation of the phagocyte during the process [224-226]. 
 
The engulfment of apoptotic cells by phagocytes often results in non-inflammatory and 
non-immunogenic response [209]. Engulfment of apoptotic cells by monocytes and 
macrophages induces reduced secretion of pro-inflammatory cytokines such as TNF-
α and IL-1 when treated with LPS [227-229]. This was partially mediated through the 
secretion of anti-inflammatory cytokines like IL-10, TGF-β, platelet activating factor 
and prostaglandin E2 [228, 229]. This above mentioned effect is applicable to DCs, 
however, the damping of immune response is not entirely coupled to the anti-
inflammatory cytokines [230-233]. Engulfment of infected apoptotic cells by DCs 
results in secretion of both pro-inflammatory (IL-6) and anti-inflammatory (TGF-β) 
that leads to a Th17 response [234]. Many studies have also shown proofs of immune 
stimulatory effect of apoptotic cells on DCs [234-241]. HMGB1 and caspase 
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activation can influence immunogenicity of apoptotic cells [242].  
 
It has been shown that activated apoptotic PBMC (ApoAct) induced DC up-regulation 
of co-stimulatory molecules, release of pro-inflammatory cytokines and proliferation of 
autologous T cells recognizing allo-antigen from engulfed apoptotic material. However, 
resting apoptotic PBMC (RestApo) were unable to generate these DC responses [240]. 
It has also been shown that murine activated apoptotic splenocytes can provide 
endogenous adjuvant activity when used in combination with a DNA vaccine to 
augment both cellular and humoral immune responses after immunization in vivo [243].  
 
The immunogenicity of apoptotic cells differs depending on the type of phagocytes, 
the type of apoptotic stimuli and the presence of pathogenic antigens. More 
knowledge is needed to understand the role played by apoptotic cells during 
pathological conditions. Nevertheless, the use of apoptotic cells or altering of 
pathways inducing apoptosis as therapeutic agent may be considered.  
 
 
1.5 Type I Interferons 
Interferon (IFN) was first described as a product of influenza virus infected chick 
embryo cells, capable of inducing resistance to infection [244]. Some years later, a 
functionally related protein, which is now called IFN-γ or type II IFN was described as 
an IFN-like virus-inhibitory protein produced by mitogen-activated human T-cells 
[245]. Interferons are expressed in low levels in physiological conditions but their 
expression is enhanced when the cells are exposed to virus or other stimuli. Apart from 
being a potent antiviral factor they also have immunomodulatory effect on immune 
cells. The interferons are divided into three types according to their receptor usage - 
type I IFNs (IFN-α, IFN-β, and IFN-ω), which bind to a specific cell surface receptor 
complex known as the IFN-α/-β receptor (IFNAR), The type II IFN (IFN-γ) binds to 
the IFN-γ receptor and type III IFNs, which signal through a receptor complex 
consisting of IL10R2 also called CRF2-4 and IFNLR1 also called CRF2-12. Twelve 
separate functional IFN-α genes and proteins and a single IFN-β gene exist in humans 
[246]. Type I interferons will be discussed in this thesis as we have used IFN-α to 
modulate HIV-1 infection in DCs.  
 
All type I IFNs are genetically and structurally very similar. They all lack introns, they 
are located on the short arm of chromosome 9 and utilize the same receptor subunits 
[247] but different type I IFNs stimulate different antiviral, anti-proliferative, and 
clinical responses [248] and are likely to stimulate different immunoregulatory 
responses as well. The expression of type I IFNs are regulated by an intracellular 
signaling pathway that is activated by PRRs. These receptors recognize molecular 
patterns specific to microorganisms, such as viral genome nucleic acids [153]. Recent 
studies have revealed that the PRRs including TLRs, RLRs, and NLRs are involved 
in discriminating self from non-self nucleic acid [249]. Early type I IFN themselves 
provide a positive autocrine feedback loop for the production of later appearing IFN 
types [250]  
 
The responses to type I IFNs are initiated by their interactions with a specific cell-
surface receptor, which has an extracellular ligand binding domain and an intracellular 
kinase domain, activated after ligand-induced dimerization [251]. The receptor has two 
chains, IFNAR1 and IFNAR2c. Both are necessary for most functions and, in the 
absence of either, there is no high-affinity ligand binding and leads to little biological 
  16 
effect. Each receptor subunit binds constitutively to a single specific member of the 
Janus kinase (JAK) family. IFNAR1 binds to tyrosine kinase 2 (TYK2) and IFNAR2 
binds to JAK1. Ligand binding induces the phosphorylation of JAK1, TYK2, 
intracellular tyrosine residues of each receptor chain and signal transducers and 
activators of transcription (STATs). Activated STATs dimerize, dissociate from the 
receptor, and translocate to the nucleus to induce the expression of interferon-
stimulated genes (ISGs) [252]. In many cells, type I IFNs activate a major transcription 
factor, IFN-stimulated gene factor 3 (ISGF3), a complex of phosphorylated STAT1, 
STAT2, and unphosphorylated interferon regulatory factor 9 (IRF-9 or p48), which 
binds to IFN-stimulated response elements (ISREs) present in the promoters of many 
ISGs. Type I IFNs can activate all seven STAT family members in different cell types, 
leading to the formation of many hetero- and homodimer pairs, as well as complexes 
with other transcription factors. 
 
In the presence of IFN-α monocyte-derived DCs get activated and express co-
stimulatory molecules and enhances T- and B-cell functions in a variety of in vitro and 
in vivo models [253-261]. Treatment of several different cell types with IFN-α leads to 
higher levels of APOBEC3 expression [262, 263]. IFN-α exhibits strong immune 
adjuvant activity in mice characterized by induction of long-term antibody production 
and immunological memory against a poorly immunogenic reference antigen [264]. 
Moreover in this study, they showed that DCs were responsible for mediating the 
adjuvant effect of IFN-α in vivo. Studies on IFN-α -receptor deficient mice showed that 
the adjuvant activity of IFN-α involves a direct effect of IFN-α on both B- and T-cells 
[265, 266]. Notably, a powerful adjuvant activity of IFN-α for commercial human 
vaccines was demonstrated in a prophylactic vaccination mouse model against 
influenza virus [267]. IFN-α can enhance recruitment of activated APCs mainly mDCs 
and pDCs at the site of vaccination [268]. 
 
The goal of “pegylating” a therapeutic protein, that is, the addition of polyethylene 
glycol (PEG) residues, is to delay clearance and increase the area under the time 
concentration curve, thus potentially enhancing efficacy compared with the native 
non-pegylated protein. Pegylation also helps to ease administration by reducing the 
frequency of dosing. Several factors influence the pharmacokinetic properties of a 
pegylated molecule, including the number of ethylene glycol residues (molecular 
weight), the configuration (linear or branched) of the PEG chain, and the amino acid 
to which the PEG is conjugated [269]. Such modification of protein tertiary structure 
with pegylation may alter efficacy and immunogenicity. 
 
IFN-α is the first biotherapeutic agent that is extensively used in clinic specially used 
in cancer treatment and in combination with Ribavirin in hepatitis C treatment [270-
273], A study showed that a low daily dose of IFN-α monotherapy exhibits potent anti-
HIV-1 activity in vivo in treatment naïve HIV-1 infected individuals without serious 
adverse effects [274]. A study on the efficacy and tolerance of IFN-α treatment of 
chronic hepatitis C in HIV-seropositive patients suggested that the treatment was 
associated with higher CD4+ cell count with no severe toxicity [275]. In natural hosts of 
SIV (such as African Green Monkeys and Sooty Mangabeys), the infection is often 
non-pathogenic despite the presence of high viral load [276]. Experiments showed that 
type I IFN production was only transient after viral inoculation in natural hosts that do 
not develop disease [277-279]. In contrast, in macaques where SIV infection is 
pathogenic, there was a local accumulation of pDCs producing high quantities of IFN-
α that can fuel the infection. It is possible that similar events take place during HIV-1 
transmission and acute infection, which may be associated with high production of 
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IFN-α and pro-inflammatory cytokines [59]. 
 
 
1.6 HIV-1 therapies and prevention strategies  
The first drug that was discovered to have an effect on HIV-1 viral replication was 
AZT (zidovudine or azidothymidine), AZT is a nucleoside reverse transcriptase 
inhibitor that blocks the conversion of viral RNA to DNA [280]. AZT initially had 
some clinical benefits, but this was short lived, as the virus evolved and produced 
resistant strains to AZT. Then the use of triple-combination therapy was found to be 
efficient against HIV-1 infection. An important breakthrough, that has changed the 
life expectancy for HIV-1 patients were the discoveries of additional classes of drugs 
and the introduction of combination therapy [281]. The initial combination of ART 
was one protease inhibitor and two nucleoside reverse transcriptase inhibitors. This 
treatment had profound effect clinically but it had many problems like side effects, 
high cost and most importantly sticking to the medication regimen to near perfection 
as even missing one dose per week could give rise to drug resistant HIV-1 strains 
[281]. Several advancements have been made with ART and the problems associated 
with these drugs have been addressed, till date ART has increased the life expectancy 
of the patients and greatly reduced the transmission of the virus. A randomized 
controlled trial that called the HPTN052 study directly examined the ability of ART 
to interrupt HIV-1 transmission from an index patient with HIV-1 to his or her sexual 
partner reveled that an early start of ART has reduced HIV-1 transmission by 96% 
[282].  
 
Several studies using ART as pre-exposure prophylaxis are ongoing. The aim is to 
investigate the protective effect of these drugs as microbicide (oral or topical pre-
exposure of the drugs) on HIV-1 acquisition [283]. One such promising study is the 
CAPRISA 004 study in South Africa, where 1% tenofovir gel was delivered into the 
vaginal vault up to 12 hours before and 12 hours within a sexual intercourse. In 2010, 
the investigators reported the first report of this study. They show a 39% reduction in 
overall acquisition of HIV-1 and a 54% in the most adherent women [284].  In 
another study, called the iPrEx study [285], HIV-1 negative men who have sex with 
men were given two oral antiviral drug daily, emtricitabine and tenofivir disoproxil 
fumarate (TDF + FTC) for up to 2.8 years. The study recorded a 44% reduction in 
HIV-1 acquisition. Eight larger trials with oral antiretroviral agents for pre-exposure 
prophylaxis are currently ongoing [282]. Substantial progresses were made in 
prevention of mother-to-child transmission by using ART as a prophylaxis [282]. 
 
The focus for development of an HIV-1 vaccine is to elucidate innate, cell-mediated 
and antibody-mediated HIV-1 restriction. Initial efforts in HIV-1 vaccine 
development were aiming to induce neutralizing antibodies. Two-phase III trials of a 
vaccine composed of gp 120 (AIDSVAX B/E), did not find any protection of healthy 
individuals against HIV-1 infection and the vaccine failed to induce high levels of 
gp120 specific antibodies [286, 287]. A T-cell vaccine called the V520 was the first 
T-cell vaccine tested in phase IIB trial and the trial is known as the STEP trial. The 
vaccine was composed of a replication-defective adenovirus type-5 vector expressing 
three HIV-1 genes (gag, pol and nef). Pre-clinical data in macaques had showed 
promising results [288-290]. 3000 individuals had been enrolled, when an interim 
analysis showed that the vaccine neither prevented HIV-1 acquisition nor reduced the 
initial viral load despite induction of T-cell responses. Moreover, there was an 
increased risk of HIV-1 acquisition in study participants who had higher pre-existing 
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levels of immunity against adenovirus type-5 [291] [292, 293]. In a trial conducted in 
Thailand, a canarypox vector vaccine (ALVAC-HIV) boosted with a recombinant 
glycoprotein vaccine (AIDSVAX B/E) led to a 31% reduction of HIV-1 incidence in 
vaccine recipients [294], which is the first large HIV-1 trial that gave a hint that it 
may be possible to develop an effective HIV-1 vaccine. Many studies have confirmed 
that male circumcision largely reduce HIV-1 transmission up to 60% [295-297]. 
Studies on HIV-discordant couples provided initial evidence of the effectiveness of the 
male condom in prevention of HIV infection [298]. Hence, it is conceivable that 
future HIV-1 preventive strategies are likely to entail a combination of advocacy for 
condom use, male circumcision, microbicides, oral pre- or post exposure prophylaxis 
as well as a HIV-1 vaccine. For ethical reasons all these preventive strategies have to 
be offered when conducting clinical trials, which will result in very high numbers of 
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2 OBJECTIVE OF THE THESIS 
 
The overall objective of the thesis was to study ways to restrict HIV-1 replication in 
dendritic cells and peripheral blood mononuclear cells. 
 
Specific objectives were as follows;  
 
1) To determine the influence of apoptotic CD4+ T-cells on HIV-1 replication in 
dendritic cells. 
2) To identify the molecules and the signaling pathways involved in dendritic cell 
maturation induced by apoptotic activated CD4+ T-cells. 
3) To investigate the antiviral effect of TNF-α and IFN-α on HIV-1 exposed 
dendritic cells.  
4) To inhibit HIV-1 replication in peripheral blood mononuclear cells using 
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3 RESULTS AND DISCUSSION 
3.1 Induction of maturation, cytokine and chemokine secretion in 
MDDC upon contact with apoptotic activated uninfected and/or 
HIV-1 infected CD4+ T-cells  (paper I) 
DCs are likely to be one of the first cells to encounter HIV-1 during sexual 
transmission and their migratory effect can contribute to the spread of the virus as they 
can act as a vehicle for capturing virus and transmitting them to CD4+ T-cell in the 
lymphoid tissues [50]. Reducing HIV-1 infection in DCs may therefore greatly reduce 
viral transmission to other susceptible cells. DC maturation suppresses HIV-1 infection 
at different stages of viral life cycle - post integration restriction at the transcription 
level [299], decreased viral fusion [300] and inhibition during reverse transcription 
[301]. Previous studies from our group suggested that apoptotic anti-CD3/CD28 - 
activated PBMCs, but not apoptotic resting PBMCs, can induce DC maturation [240]. 
In paper I, we first investigated whether apoptotic HIV-1 infected activated CD4+ T-
cells were able to induce DC maturation. For the experimental set up, we used anti-
CD3/CD28 mAbs to activate CD4+ T-cells for 24 hours followed by infection with 
HIV-1BaL. Cells were γ-irradiated to induce apoptosis and added to the immature DC 
cultures (in vitro–differentiated monocytes cultured for 6 days in the presence of IL-4 
and GM-CSF) immediately after radiation exposure, to allow early apoptotic events 
to occur in the co-cultures [240, 302-304]. Longer exposures to activation, or 
activation induced cell death, as well as resting apoptotic cells do not promote DC 
maturation and such cells are instead involved in peripheral tolerance mechanisms 
[240, 305-307]. This is the reason why we induced apoptosis no longer than 3-4 days 
after activation of the T-cells.  
 
Immature DCs co-cultured with apoptotic activated (ApoAct) or apoptotic HIV-1 
infected (ApoInf) CD4+ T-cells where analyzed for expression of the co-stimulatory 
molecule CD86 after 72 hours or 7 days. DCs co-cultured with ApoAct or ApoInf 
induced CD86 expression significantly as compared with medium control both after 
72 hours and 7 days of culture. DCs exposed to HIV-1BaL viral particles did not 
significantly up-regulate CD86 after 72 hours or 7 days of culture as compared with 
the medium control. DC encounters infected or uninfected apoptotic cells that contain 
viral particles in vivo. We therefore investigated whether the induction of DC 
maturation was functional in the presence of viral particles. We observed that the 
maturation signal provided by the ApoAct or ApoInf occurred even in the presence of 
free HIV-1BaL, and the efficiency of induced CD86 expression was comparable to that 
of the positive control. We also studied the expression of CD83, another molecule 
associated with DC maturation and functional antigen-presenting capacity whose 
expression was similar to that of CD86 but with a tendency of lower expression than 
CD86.  
 
DC maturation results in secretion of cytokines [159]. To asess the cytokine 
production in our culture system, we collected supernatants from the co-cultures after 
4, 8 and 24 hours. Multiplexed cytokine assay, was used for simultaneous analyses of 
MIP-1α, MIP-1α, TNF-α, IL-10, IL-12p70, and MCP-1. Supernatants from DCs co-
cultures with apoptotic anti-CD3- and anti-CD28-activated CD4+ T-cells, either 
uninfected or HIV-1 infected, showed a significant induction of TNF-α as compared 
with medium control after 24 hours of co-culture. Also supernatants from DC co-
cultured with ApoAct or ApoInf that contained exogenous HIV-1BaL, showed a 
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significant induction of TNF-α. IL-12p40 or IL-12p70 molecules were not found in 
any of the above mentioned culture supernatants. There was no induction of the 
above mentioned cytokines in the DCs co-cultured with apoptotic resting CD4+ T-
cells. We also detected a significant induction of chemokines MCP-1, MIP1-α and 
MIP-1β secretion in the supernatants from the DC co-cultured with ApoAct 
regardless of infection with HIV-1BaL and also in the ApoAct and ApoInf co-cultures 
with exogenous HIV-1BaL. There was no significant secretion of these cytokines from 
the CD4+ apoptotic T-cells per se.   
 
These findings show that both ApoAct and ApoInf are able to provide a maturation 
signal to immature DCs even in the presence of exogenous HIV-1. Moreover, that the 
free viruses alone do not induce maturation in DCs showing that the added viruses do 
not contain any bystander soluble factors influencing DC maturation. The HIV-1 
infection of activated CD4+ T-cells does not seem to interfere with the DC 
maturation signal. However, a requirement for the induction of maturation signal is 
that the CD4+ T-cells have to be activated before apoptosis induction. In addition, 




3.2 APOBEC3G- and TNF-alpha contribute to reduction of HIV-1 
infection in MDDC when co-cultured with apoptotic activated CD4+ 
T-cells  (paper I) 
HIV-1 infection in the co-cultures was determined by quantifying the percentage of 
p24 expressing DCs using flow cytometry [190, 302]. Co-culture of DCs with 
ApoAct with and without HIV-1 infection, resulted in a significantly reduced 
percentage of p24+ DCs as compared with DCs exposed only to HIV-1BaL. There was 
no reduction of p24+ DCs when co-cultured with ApoRest. Both autologous and 
allogeneic ApoAct co-cultures showed similar reduction in HIV-1 p24 and similar 
induction of CD86 expression. Similar results were obtained when infection 
efficiency was measured using quantitative PCR, which showed a ten fold decrease in 
viral DNA copies when ApoAct (infected or uninfected) were co-cultured with DCs 
and there was a decrease in the relative proportion of integrated proviral DNA when 
assessed using Alu-PCR. There was no effect on viral infection when the DCs were 
co-cultured with ApoRest. Serial dilution of ApoAct demonstrated that the increase in 
numbers of ApoAct in the co-culture resulted in decrease in percentage of p24+ DCs. 
Similar results were obtained when kinetic experiments were performed. We detected 
a reduction in p24 when the DCs were exposed to HIV-1BaL for 30 minutes, 1 hour or 
2 hours prior to the addition of ApoAct, similarly p24 expression was reduced when 
DCs were first co-cultured with ApoAct for 30 minutes, 1 hour or 2 hours prior to 
infection. The inhibition effect of the ApoAct was detected with three other isolates 
(HIVIIIB and two other primary isolates). 
 
As there was significant amount of pro-inflammatory cytokines and chemokines 
released into supernatants, we want to assess if there was any soluble factors involved 
in the reduction of HIV-1 infection. We therefore collected supernatants after 24 
hours of DC/ApoAct co-culture to be used as Conditioned medium (CM). There was 
reduction in p24 expression in DCs exposed to HIV-1BaL and CM as compared with 
DCs exposed to HIV-1BaL alone. There was also a dose-dependent response in the 
reduction of p24 expression in HIV-1BaL infected DCs after exposure to different 
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volumes of CM. The addition of blocking antibody to TNF-α restored p24 expression 
but the addition of blocking antibodies to MIP-1α, MIP-1β, IFN-γ and RANTES to 
the CM did not restore p24 expression. The HIV-1 inhibitory effect by ApoAct was 
partially lost in the presence of TNF-α mAb. In addition, the TNF-α mAb blocked 
CM-mediated up-regulation of CD86 in DCs. There was a dose dependent inhibition 
of HIV-1 infection in DCs when treated with different concentrations of recombinant 
TNF-α. The HIV-1 inhibitory effect by TNF-α was lost in the presence of TNF-α 
mAb. These findings provide evidence for a partial HIV-1 inhibitory effect mediated 
by TNF-α upon ApoAct and DC co-cultures.   
 
CM added 2 hours or 16 hours after HIV-1 exposure did not significantly reduce p24 
expression in DCs but ApoAct added 2 hours or 16 hours after HIV-1 exposure 
reduced HIV-1 p24 expression in DCs. This data suggested that there might be 
intrinsic factors involved in restricting HIV-1 replication in the DCs. We therefore 
assessed the mRNA level of the host antiviral factor APOBEC3G in the DCs before 
and after co-culture. We observed an induction of APOBEC3G mRNA in the DCs 
co-cultured with ApoAct (irrespective of autologous or allogeneic origin of apoptotic 
cells) and also in LPS stimulated DCs after 6 hours. We did not detect APOBEC3G 
mRNA after 2 hours, this shows that the mRNA detected was expressed in DCs but 
not in ApoAct. To investigate the role played by the APOBEC3G in inducing the 
reduction of HIV-1 infection, we silenced the APOBEC3G expression by using 
siRNA. There was a significant increase in p24 expression after silencing of 
APOBEC3G in DCs co-cultured with ApoAct. To verify that APOBEC3 proteins 
exerted a function to restrict HIV-1 infection in the DC, we sequenced a region in env 
from the DNA obtained from HIV-1 infected DC co-cultured with ApoAct or 
ApoRest and measured the frequencies of G-to-A mutations using the program 
HYPERMUT 2.0. Three clones had significant p<0.05, Fisher exact p-value in co-
cultures with ApoAct, while none of the clones sequenced from ApoRest co-cultures 
were found to have significant induction of G-to-A hypermutations. G-to-A mutations 
were detected both in the GG and GA context. There was a significant difference in 
the mutation frequency in clones obtained from ApoAct DC co-cultures compared 
with ApoRest.  
 
The above data suggest that ApoAct can induce maturation and pro-inflammatory 
cytokine secretion in DCs. Alloantigen-induced immune responses may reduce HIV-
1 susceptibility in CD4+ T-cells [308, 309]. Here we show that both allogeneic and 
autologous ApoAct are able to provide DCs with a maturation signal and 
upregulation of APOBEC3G mRNA. TNF-α treatment can inhibit HIV-1 infection in 
these DCs and the HIV-1 inhibitory effect by ApoAct can be partially explained by 
release of TNF-α. TNF-α can inhibit or promote viral replication depending on the 
target cell type [310]. CM added 2 hours or 16 hours after HIV-1 exposure did not 
significantly reduce p24 expression in DCs. It is therefore possible that the soluble 
factors in the CM are restricting the viral replication only at a very early stage of viral 
life cycle. Further studies are required to understand the mechanism by which the 
TNF-α exerts inhibition of viral replication in DCs. Several other viral restriction 
factors could play a role in TNF-α mediated HIV-1 inhibition. One such candidate 
worth studying is SAMHD1, which is expressed in cells of the myeloid lineage, 
which inhibits viral replication by interfering at an early step of the viral life cycle 
[90]. The siRNA silencing results demonstrated that antiviral factor APOBEC3G is 
crucial for exerting the HIV-1 inhibition effect. Vif counteracts APOBEC3G [15, 
311], in this study we used a complete virus that is capable of producing active Vif, 
still we detected an induction of G-to-A hypermutation. One possible explanation 
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could be that other APOBEC3 molecules might be involved in reduction of viral 
replication in the present system. Recently it has been shown that MDDC express 
APOBEC3A and it is involved in the restriction of viral replication [125]. The high 
level of expression of these molecules might have overcome the Vif mediated 
degradation. In addition, DCs do not replicate HIV-1 as effectively as activated CD4+ 
T-cells, therefore the level of Vif is also reduced and the antiviral activity of 
APOBEC may prevail. The pool of APOBEC3 molecules already present in the target 
cells can efficiently restrict replication of the incoming virus as the Vif is absent in 
this scenario. The expression levels of these molecules vary greatly between the cell 
types. Based on the results from an experiment where CM was added 2 hours or 16 
hours after HIV-1 exposure did not significantly reduce p24 expression in DCs 
showing that the CM restriction happens before integration but ApoAct added 2 hours 
or 16 hours after HIV-1 exposure reduced HIV-1 p24 expression in DCs shows the 
viral inhibition occurs after integration. In addition the data from the Alu-PCR 
revealed the presence of integrated DNA in DCs co-cultured with ApoAct, from the 
above data it is possible to conclude that the inhibition is likely to occur both at pre- 






3.3 Both cellular and supernatant fractions from activated apoptotic 
lymphocytes are required for stimulation of DC maturation signal 
(paper II) 
Data from our previous reports [240] and paper 1 suggested that ApoAct (PBMC or 
CD4+ T-cells) can induce DC maturation. Here we investigated the molecules and the 
signaling pathways involved in the DC maturation by ApoAct. In this study, we used 
activated apoptotic PBMC (ApoAct PBMC). We started investigating both the cellular 
and soluble factors, as theoretically, both of them can induce DC maturation. We co-
cultured immature DCs with cellular or soluble fractions derived from ApoAct PBMC. 
We detected partial up-regulation of the maturation markers CD80 and CD86 on DCs 
under both conditions with a more prominent effect by the cellular fraction. When we 
used a transwell system to co-culture DC / ApoAct PBMC, we observed a partial up-
regulation of maturation markers on DCs. This effect was not detected in co-cultures 
containing ApoRest PBMC. Cultures containing neutralizing antibodies against TNF-
α, showed reduced up-regulation of co-stimulatory molecules, while the cultures with 
neutralizing antibodies against HMGB1 did not affect the up-regulation of co-
stimulatory molecules. 
 
To investigate molecules engaged in the cellular fraction, DCs / ApoAct PBMC co-
culture was incubated with neutralizing antibodies against the integrins CD18, CD11a 
and CD11b, which resulted in inhibition of up-regulation of co-stimulatory molecules. 
αvβ5 is an integrin previously shown to be involved in uptake of apoptotic cells [312] 
but we were not able to block DC maturation by adding anti- αvβ5 antibodies. Blocking 
phagocytosis of apoptotic cells with cytochalasin D did not inhibit induction of 
maturation signal, showing that phagocytosis of apoptotic cells is not required, but 
rather that cell-cell-contact is sufficient to trigger DC maturation signaling. Inhibition 
of up-regulation of co-stimulatory molecules was observed in the presence of 
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neutralizing antibodies against DC-SIGN and also in the presence of anti-TLR4 
antibodies. The role of TLR4 was further conformed by the silencing of TLR4 using 
siRNA. The role of TLR4 in DC maturation in our system was assessed in vivo using 
TLR4-/- mice and MyD88-/- mice. Wild-type and TLR4 knockout mice were injected 
with activated apoptotic splenocytes in combination with human serum albumin (HSA) 
as a model protein antigen. A previous report from our laboratory showed an adjuvant 
effect by activated apoptotic splenocytes in combination with a DNA vaccine in mice 
[243]. We detected significant induction of anti-HSA antibodies in wild-type mice 
when activated apoptotic splenocytes were used as adjuvant in combination with HSA. 
However, we did not detect significant induction of anti-HSA antibodies in the 
knockout mice demonstrating a role for TLR4 in providing the adjuvant effect in vivo. 
Resting apoptotic splenocytes did not provide any adjuvant effect neither in wild-type 
nor in the knockout mice. 
 
3.4 Involvement of multiple signaling pathways in DC co-cultured with 
activated apoptotic PBMC (paper II) 
 
Several intracellular signaling molecules and pathways have been suggested to be 
involved in DC maturation signaling and available reports clearly indicate that the role 
of each pathway is stimulus specific having both positive and negative regulatory role. 
Therefore, in order to get a clear picture, it is important to characterize the role of these 
pathways in specific contexts. p38, ERK and JNK MAPKs were rapidly activated in a 
dose dependent manner in the DC / ApoAct PBMC co-cultures. NFκB and AP-1 
transcription factor family are involved in DC activation, pro-inflammatory cytokine 
secretion and also in up-regulation of co-stimulatory molecules [313]. Both ApoAct 
and ApoRest induced degradation of inhibitory IκB protein, but full activation of NFκB 
p65 was achieved only in DCs co-cultured with ApoAct. In addition, ApoAct, but not 
ApoRest, induced activation of AP-1 transcription factor family members c-Jun and c-
Fos in a time dependent manner. Inhibition of p38, ERK and JNK MAPKs using 
specific inhibitors revealed that p38 and JNK MAPK were required for maturation 
signaling in DCs. ERK MAPK did not seem to be involved in DC maturation by 
ApoAct PBMC. Inhibition of PI3K-AKT, Src family of tyrosine kinases and Raf-1 
suggested that PI3K-AKT and Src family of tyrosine kinases were involved in the DC 
maturation signaling upon contact with ApoAct. However, the up-regulation of co-
stimulatory molecules in DC remained unaffected when a Raf-1 inhibitor was used 
suggesting that the activation signal is not DC-SIGN dependent. Activation of 
AKT/protein kinase B (PKB), a major effector of PI3K, has been reported to be a 
critical factor in both activation and survival of DCs [314, 315]. We observed that both 
release of pro-inflammatory cytokines and expression of CD80 and CD86 were 
significantly inhibited in PP1 and PP2 pretreated DCs after co-cultured with ApoAct. 
This shows that apart from regulating the release of pro-inflammatory cytokines, Src 
family of tyrosine kinase could also regulate the expression of maturation markers on 
DCs. Treatment of DC / ApoAct PBMC with neutralizing antibodies against TLR4 and 
β2-integrins reveled that AKT activation is dependent on TLR4 and β2-integrins. β2-
integrin dependent cell-contact, TLR4-PI3K/Akt, and Src family of tyrosine kinases 
were also required for activation of p38 MAPK dependent activation of NFκB whereas 
neutralizing antibody against DC-SIGN had no effect on ser-536 phosphorylation of 
p65 which further supports that NFκB was not activated by DC-SIGN. Further, we 
observed that TLR4, DC-SIGN and Src family of tyrosine kinases regulated JNK 
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MAPK activation and activation of c-Jun and c-Fos was regulated by p38 MAPK, JNK 
MAPK and Src family of tyrosine kinases (Fig. 3).  
 
The above data suggest that activation of p38 MAPK occurred in a DC-SIGN 
independent but TLR4 and CD18 dependent manner. However, activation of JNK 
MAPK was dependent on TLR4, DC-SIGN and CD18. These findings suggest a 
cooperative signaling between these molecules upon DC/ApoAct contact. It has been 
reported that DC-SIGN and TLR4 cooperate to induce an inflammatory phenotype in 
human DCs in response to S. manosi worm glycolipids [316]. In this study we could 
decipher some of the molecules involved the DC maturation signaling by ApoAct 
PBMCs. But it is not clear from the data whether the integrins involved in triggering 
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3.5 IFN-alpha inhibits HIV-1 replication and up-regulates APOBEC3 
molecules without inducing maturation in MDDC (paper III) 
In paper I we demonstrated that TNF-α plays a role in reducing HIV-1 replication in 
DCs. In this study, we treated MDDCs with TNF-α or IFN-α and compared their 
ability to induce maturation (in terms of up-regulation of co-stimulatory molecules) and 
inhibit viral replication in MDDCs. We treated DCs with 3 concentrations of TNF-α  
(0.3, 3, 30 ng/ml single-dose increasing concentrations) and 3 concentrations of 
pegylated IFN-α2b (102, 103, 104 U/ml single-dose increasing concentrations). We used 
a pegylated IFN-α in our studies as the addition of PEG may delay clearance of the 
protein. We found that IFN-α2b did not up-regulate co-stimulatory molecules at lower 
concentrations i.e. (102, 103 U/ml). At the higher concentration both TNF-α (3, 30 
ng/ml) and IFN-α2b (104 U/ml) induced up-regulate co-stimulatory molecules.  
 
DC maturation can inhibit viral replication at different stages of viral life cycle - post 
integration restriction at the transcription level [299], decreased viral fusion [300] and 
inhibition during reverse transcription [301]. Here, we compared TNF-α and IFN-α for 
their ability to inhibit HIV-1 replication in DCs. HIV-1BaL exposed DCs were cultured 
with these cytokines at different concentrations as mentioned above. TNF-α could 
inhibit HIV-1 replication significantly only at higher concentration (30 ng/ml) but IFN-
α2b significantly reduced viral replication at all the concentrations used (102, 103, 104 
U/ml). Even the lower concentration of IFN-α2b, which was not able to mature DCs, 
could significantly inhibit HIV-1 replication. We observed similar results with respect 
to DC maturation and HIV-1 restriction when we used non-pegylated IFN-α ( IFN-
α2A and IFN-αΑ/D) at the same concentration as IFN-α2b. 
 
Then we investigated whether there was an up-regulation of antiviral host factor 
APOBEC3 molecules in these DCs, as we detected elevated APOBEC3G expression in 
matured DCs in paper I. DCs treated with TNF-α did not show significant expression 
of APOBEC3G (A3G), APOBEC3F (A3F) or APOBEC3A (A3A) mRNA even at 
concentration when viral replication was inhibited. On the other hand, DCs treated with 
IFN-α2b had a dose dependent induction of expression of all the three APOBEC3 
mRNA.  
 
Cloning and sequencing of an env region in the DNA obtained from the HIV-1 exposed 
DC treated with low concentration of pegylated IFN-α2b (102 U/ml) revealed 
significant number of G-to-A hypermutations. Twelve out of the sixty clones had 
significant mutation rate (Fisher exact p-value <0.05). The G-to-A mutations occurred 
in both GG and GA contexts. 
 
In summary, we showed that IFN-α can restrict viral replication in DCs without 
inducing maturation in DCs and that the viral restriction can be partly explained by the 
expression of APOBEC3 mRNA. Whereas TNF-α can induce maturation and restrict 
viral replication in DCs, the APOBEC3 molecules do not play a major role in TNF-α 
mediated viral restriction. However, siRNA experiments are required to fully reveal the 
role of APOBEC3 molecules in these experimental settings.  
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HIV-1 infection is characterized by acute and chronic immune activation of which 
some may be due to dysfunctional cytokine and IFN-α production [59]. SIV infection 
is often non-pathogenic in African Green Monkeys and Sooty Mangabeys despite the 
presence of high viral load [276] Experiments showed that type I IFN production was 
only transient after viral inoculation in natural hosts that do not develop disease [277-
279] but in macaques where SIV infection is pathogenic, pDCs accumulates locally and 
produce high quantities of IFN-α that can fuel the infection. It is possible that similar 
events can take place during HIV-1 transmission and acute infection that can be 
associated with high production of IFN-α and pro-inflammatory cytokines [59]. High 
production of IFN-α and pro-inflammatory cytokines such as TNF-α will induce DC 
maturation and trigger migration of DCs into lymphnodes facilitating dissemination of 
the infection [317]. The above data suggests that a window of low IFN-α concentration 
can inhibit viral replication without inducing DC maturation. We noticed a high 
induction of A3A mRNA expression by IFN-α2b. In addition, treatment of DCs with 
IFN-α2b introduced G-to-A hypermutations that occurred in both GG and GA contexts 
in the proviral DNA. A recent report demonstrated that A3A is preferentially expressed 
in myeloid cells compared with peripheral blood lymphoid cells and restricts HIV-1 
replication in myeloid cells [125]. A3A can induce mutations in GG as well as in GA 
contexts [311]. Our finding corresponds with the above reports. We have also observed 
induction of A3G and A3F mRNA by IFN-α2b and these molecules were reported to 
be involved in viral restriction.  
 
TNF-α on the other hand could only limit replication in MDDCs in a relatively high 
concentration (30ng/ml) that also induced DC maturation. None of the concentrations 
of TNF-α (0.3-30ng/ml) that we used in the present study showed induction of 
APOBEC3 family proteins. TNF-α had been reported to enhance viral replication in 
monocyte derived macrophages [310]. More experiments has to be done to decipher the 
mechanism by which TNF-α limits viral replication in MDDCs, which may help 




3.6 Proteasome inhibitors blocked HIV-1 LTR-mediated gene 
expression both in vitro and in vivo (Paper IV) 
NF-κB is a ubiquitous transcription factor critical in inflammation and immunity. 
HIV-1 LTR promoter has active NF-κB binding sites [318]. Various reagents 
targeting the NF-κB signaling pathway have been examined for their inhibitory 
effects on HIV-1 [47]. Bortezomib is the first FDA-approved proteasome inhibitor, 
which is used in clinic for the treatment multiple myeloma [319]. Here we studied the 
effect of two proteasome inhibitors Bortezomib and MG132 on the HIV-1 LTR 
promoter activity. HIV-1 LTR-luciferase (pLTR-Luc) construct was transiently 
transfected in different cell lines (A20, Jurkat and HEK239T cells) and were 
incubated overnight with MG132 or Bortezomib. We observed a reduction in the 
expression of luciferase in these cell lines in the presence of proteasome inhibitors. 
We obtained similar results when the HIV-1 LTR-GFP (pLTR-GFP) transfected cells 
were treated with MG132.  
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To examine if the proteasome inhibitors can block the HIV-1 LTR- mediated gene 
expression in vivo we employed an in vivo gene delivery technique known as the 
hydrodynamic infusion method. pLTR-Luc was introduced into the liver of mice. The 
HIV-1 LTR-promoter was functional and highly active in hepatocytes. When these 
animals were injected with Bortezomib we observed a reduction of reporter gene 
expression, which is consistent with the 




3.7 Proteasome inhibitors blocks HIV-1 replication and inhibit 
expression of IL-2 inducible T cell kinase in PBMC (PAPER IV) 
 
A Tec-family tyrosine kinase - IL-2 inducible T cell kinase (Itk), which is involved in 
T-cell activation and development, has been shown to play a vital role in HIV-1 
replication [320]. Inhibition of Itk expression has been shown to block HIV-1 
replication at multiple stages of its life cycle [320]. We observed a reduction in base 
line expression of Itk in resting PBMC by both the proteasome inhibitors in a dose-
dependent manner. In addition, the proteasome inhibitors when added during the 
activation of PBMC with PHA and IL-2 blocked activation-dependent Itk induction 
in PBMC. However, we observed a moderate effect on the expression of Itk when 
pre-activated PBMC (activated with PHA- and IL-2 for 72 hours) were treated with 
these drugs. On the other hand, the steady state levels of NF-κB p65 fell sharply in 
these pre-activated PBMC when treated with the proteasome inhibitors. Thus, the 
proteasome inhibitors effectively suppress induction of Itk expression during PHA 
activation, but only moderately after activation. However, treatment with these drugs 
downregulate steady-state levels of Itk in resting PBMC. 
 
To examine whether the proteasome inhibitors can inhibit viral replication, we 
infected PBMCs with HIV-1BaL in the presence of either of the two proteasome 
inhibitors or in the presence of the antiretroviral drugs Indinavir (IND) or 
azidothymidine (AZT). When we assessed the supernatant for reverse transcriptase 
(RT) activity, we found that the proteasome inhibitors significantly restricted HIV-1 
replication in PBMCs as efficiently as the antiretroviral drugs that are used in HIV-1 
therapy. The HIV-1 exposed PBMCs were treated in combination with proteasome 
inhibitors (Bortezomib or MG132) and the antiretroviral drugs. The combination of 
proteasome inhibitor with AZT or IND did not exhibit synergistic effects but they did 
inhibited viral replication significantly without severely affecting the cell viability.  
 
Proteasome inhibitors effectively suppressed induction of Itk expression in PBMC 
during PHA activation. But in the PBMC that were pre-activated, the suppression of 
expression level of Itk by the proteasome inhibitors was moderate. This differential 
effect on Itk expression by proteasome inhibitors depending on the activation status 
of the PBMC might also affect the HIV-1 inhibition by proteasome inhibitors 
differentially. The time point of the treatment of PBMC with proteasome inhibitors 
might have an impact on the inhibition of viral replication. To investigate this, we 
employed three different treatment conditions. In “Treatment 1”, the pre-activated 
PBMC (activated with PHA- and IL-2 for 48 hours) was treated with Bortezomib at 
the time of infection. We then observed that 2.5 nM of Bortezomib was required for 
significant reduction of RT-activity and also to reduce viral DNA. In “Treatment 2” - 
we added Bortezomib at the time of activation (together with PHA and IL-2) and 
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washed it away during infection. Bortezomib at a concentration of 1.25 nM and 2.5 
nM, reduced viral RT-activity. But an efficient reduction in viral DNA was noticed 
only with 2.5nM of Bortezomib.  In “Treatment 3”, PBMCs were continuously 
treated with Bortezomib throughout the experiment. We observed an effective 
reduction in RT-activity in both the concentration of Bortezomib used. Even though 
we measured a decrease in viral DNA by both concentrations, we detected a robust 
reduction in HIV-1 DNA only when 2.5 nM of Bortezomib was used. 
 
Collectively, proteasomes inhibitors can inhibit HIV-1 LTR activity and also restrict 
viral replication in PBMCs. Most of the current antiviral drugs are directed against viral 
targets, which can lead to the development of drug resistant viral strains. HIV-1 
preferentially replicates in proliferating CD4+ T-cells, partly by taking advantage of the 
activated host transcription machinery [321]. Proteasome inhibitors targets host 
transcription factor and it is less likely that the virus develops resistance to the 
proteasome inhibitors. By using proteasome inhibitors one can inhibit the degradation 
of IκB and thereby maintain the inactive form of NF-κB in the cytosol, which in turn 
inhibit viral replication. Apart from NF-κB, proteasome inhibitors reduce the 
expression of Itk and also interfere with the T-cell activation and thereby affecting viral 
replication. A possible drawback of targeting Itk can be that it might affect immune 
functions and is relatively toxic. Reports from Itk -/- mice suggest that these mice are 
still able to mount an immune response upon infection. The results show that CTL 
responses are reduced in the absence of Itk whereas antiviral B-cell responses are not 
affected [322]. Vif counteracts antiviral host factors APOBEC3 molecules by 
mediating these molecules to undergo proteasome dependent degradation. There are 
also other host factors, such as SAMDH1 and Tetherin, that undergo degradation 
through the ubiquitin proteasome pathway. There is a theoretical possibility that the use 
of proteasome inhibitors may restore antiviral factors in the host. As a plethora, of 
molecules are regulated by ubiquitin proteasome pathway, restricting these molecules 
on a long-term basis might not be ideal because of side effects. Proteasome inhibitors 
may have the possibilities to be used as a intermittent third line treatment in HIV-1 
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4 CONCLUDING REMARK  
Dendritic cells are located in mucosal and lymphoid tissues and their location in the 
mucosa makes them one of the first cells to encounter HIV-1 during sexual 
transmission. Apart from priming the T-cells, the DCs can also contribute to the spread 
of the virus to CD4+ T-cells through mere cell-cell contact and by hijacking the virus 
from the site of infection and migrating to the lymph nodes were it meets abundance of 
CD4+ CCR5+ cells. It has been shown that HIV-1 can infect DCs acting as a viral 
reservoir in vivo [323]. Protecting DCs from acquiring infection may therefore 
theoretically, reduce the transmission of the virus to vulnerable cells. DC maturation 
reduces HIV-1 infection at different stages of viral life cycle - post integration 
restriction at the transcription level [299], decreased viral fusion [300] and inhibition 
during reverse transcription [301]. On the other hand, induction of DC maturation was 
shown to increase infection to T-cells in trans. In our attempt to restrict viral replication 
in primary cells, we first used apoptotic cells to induce DC activation. Apoptotic cells 
are know to have a immune-dampening effect on the immune system but many 
emerging reports and the previous work from our group has suggested that they can be 
potent immune activators in some circumstances. 
 
Co-culturing of DCs with apoptotic activated CD4+ T-cells resulted in the maturation of 
DCs and also induced the secretion of pro-inflammatory cytokines and chemokines. 
But resting apoptotic CD4+ T-cells did not exert this effect on DCs. The capacity to 
activate DCs was not affected if the apoptotic cells were infected with HIV-1 and also 
occurred in the presence of free virus in the co-cultures. The apoptotic cells can either 
be allogeneic or autologous to induce this effect. One requirement is however that the 
apoptotic cells have to be activated before co-culturing. These findings were in line 
with previous data from our group using apoptotic PBMCs. DCs maturation can lead to 
inhibition of HIV-1 replication. We found that apoptotic activated cells, when co-
cultured with HIVBaL exposed DCs, reduced the percentage of p24+ DCs. Again, the 
resting apoptotic cells could not mount this effect. We also observed that two factors 
played a major role in inhibiting viral replication. The first one was the pro-
inflammatory cytokine TNF-α, which is partly involved in the restriction of HIV-1 in 
DCs exemplifying the differential function of TNF-α during HIV-1 infection. The 
second, was the host intrinsic factor APOBEC3G, which we demonstrated to be 
involved in restriction of HIV-1 in DCs / ApoAct co-cultures. Analysis of more 
intrinsic factors, such as other APOBEC3 molecules (especially A3A and A3F as we 
observed a significant G-to-A hypermutations in the proviral DNA), TRIM5α, SAMHB 
1 might have shed more light on the mechanism by which the ApoAct / DC co-culture 
inhibits viral replication. The results from the PCR analysis show that there is no 
complete elimination of the virus and the inhibition occurs both at the pre- and post- 
integration level. We have also noticed that prolonged activation of CD4+ T-cells prior 
to the induction of apoptosis reduced its ability to induce maturation in DCs. These 
above data suggest the apoptotic cells may induce host factors during HIV-1 infection. 
It has to be noted that HIV-1 infection in vivo leads to aberrant immune activation, a 
thorough investigation on how efficient the lymphocytes obtained form HIV-1 infected 
individuals can exert an antiviral effect on DCs will provide better understanding of 
HIV-1 pathogenesis involving interactions between HIV-1, apoptotic cells and DCs.  
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When we made an attempt to characterize the molecules and the signaling pathway 
involved in the maturation of DCs by apoptotic cells we found that both soluble and 
cellular factors were involved. Using blocking antibodies against TNF-α, revealed 
that TNF-α is involved in the maturation of DCs. ApoAct per se secreted very low 
amount of TNF-α. Hence, it was the TNF-α secreted by the DCs that acted in an 
autocrine manner to induce maturation. HMGB1 did not play a role in inducing DCs 
maturation in our system. When we looked for PRRs and their involvement in DC 
maturation, we found that DC-SIGN and TLR4 were engaged. It is known that apart 
from foreign antigen DC-SIGN binds to number of endogenous ligands like ICAM-2 
and ICAM-3 to induce DC tolerance [324-326]. Here, our data suggest that DC-SIGN 
is involved in inducing DC maturation in our co-cultures. Using TLR4-/- and Myd88-/- 
mice, we found TLR4 involvement for the adjuvant effect in vivo. Blocking CD18 
using antibodies revealed that β2-integrin is one of the molecules indulged in 
inducing DCs maturation. In the present study we could not clearly distinguish 
whether the integrins from the DCs or the apoptotic cells are responsible for the DCs 
maturation signal. It could be from either side.  
 
We found that both AKT and Src family of tyrosine kinases regulated activation of 
MAPKs in DCs that were co-cultured with ApoAct. Although we observed a strong 
activation of MAPK members ERK, p38 and JNK, signaling, only p38 and JNK 
MAPK is required for ApoAct-induced DC maturation. Activation of ERK MAPK 
seems to be linked to some other response in DCs. Activation of p38 MAPK occurred 
in a DC-SIGN independent but TLR4 and CD18 dependent manner, whereas 
activation of JNK MAPK was dependent on TLR4, DC-SIGN and CD18, suggesting 
a cooperative signaling between these molecules. NF-κB and AP1 family of 
transcription factors play an important role in DC activation and release of pro-
inflammatory cytokines.  Here we show that that ApoAct-induced DC activation 
involves both NF-κB and AP1 family of transcription factors. We have identified 
some of the molecules involved during the DC maturation when co-cultured with 
ApoAct. Several cell surface molecules, signaling molecules and pathways were 
reported previously in other systems. These previous studies and our data suggest that 
the molecules and the pathway involved are stimuli specific. 
 
When we treated TNF-α and IFN-α in DCs, we found that both cytokines can induce 
DC maturation. But in case of TNF-α, the DCs had to be treated at a concentration in 
which maturation occurred in order to inhibit HIV-1 replication. This was not the case 
with IFN-α. IFN-α could exhibit antiviral activity at lower concentrations without 
inducing DCs maturation. The antiviral exerted by IFN-α can be partly explained by the 
up-regulation of expression of APOBEC3 mRNA (A3G, A3F, A3A) and significant 
induction of G-to-A hypermutations in the proviral DNA. We also found that DC 
maturation by TNF-α does not up-regulate the expression of APOBEC3 mRNA. This 
effect of IFN-α on the DCs may be exploited for HIV-1 prevention. Animal studies 
suggest that concentrations of IFN-α are crucial for the differential effect of IFN-α in 
inhibiting viral replication. IFN-α can be used locally at the site of infection at low 
concentration so that the DCs do not attain the migratory ability and at the same time 
can restrict viral replication in them. This may prevent the DCs from migrating to the 
lymph nodes and spreading the infection to the CD4+ T-cells.  
 
We used proteasome inhibitors (one of them is in clinical use to treat multiple 
myeloma) to reduce viral infection in PBMCs. The proviral gene expression is highly 
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dependent on host transcription factor NF-κB. Here we showed that proteasome 
inhibitors reduced the NF-κB activity both in vitro and in vivo and that they can 
restrict viral replication in PBMCs without significantly affecting the cell viability. 
However, the proteasome inhibitors were able exhibit this effect only at a very 
narrow concentration and also the inhibitors had to be continuously present in the 
culture for inhibiting the viral replication efficiently. It remains to be investigated 
whether newer generations of proteasome inhibitors with better toxicity profiles will 
have effective antiviral activities. The proteasome inhibitors not only affect NF-κB 
but also Itk, which is critical for T-cell activation and viral replication. Several 
molecules in the host that are crucial for viral replication is regulated by ubiquitin 
proteasome pathway, for example the APOBEC3 family molecules. The proteasome 
inhibitors may restore the level of antiviral factors like APOBEC3 and restrict the 
expression of proviral factors such as Itk. Most of the current anti-HIV-1 drugs are 
against viral targets and the virus can efficiently develop resistance strains to these 
drugs but targeting the host factors can solve this problem. Again, targeting host 
molecules can disturb the integrity of the host cells and also some of these molecules 
are involved in the immune activation. Restricting these molecules on a long-term 
basis might not be ideal as they induce several side effects. Proteasome inhibitors 
may have the possibilities to be used as a third line treatment in HIV-1 infection or as 
a microbicide locally at the site of HIV-1 exposure.  
 
Both ApoAct and IFN-α were able to up-regulate expression of APOBEC3 molecules 
in DCs and proteasome inhibitors may also restrict degradation of APOBEC3 
molecules. During natural infection, the virus has an active Vif to counteract 
APOBEC3 and one can argue that the Vif might lead to low expression of APOBEC3 
molecules which in turn will result in introduction of sub lethal mutations which 
might add up to the viral genetic diversity and subsequently can lead to more potent 
viral strains. In our system, we used virus that has a fully functional Vif but still we 
could detect an inhibitory effect exerted by APOBEC3 molecules. There is a 
possibility that the level of the APOBEC3 molecules induced in our system could 
have efficiently evaded Vif mediated degradation. Moreover, the pool of APOBEC3 
molecules already present in the target cells can efficiently restrict replication of the 
incoming virus, as the Vif is absent in this scenario. Up-regulation of these molecules 
at the time of infection or during the viral entry into the target cell can prove lethal for 
the virus. The evolution of the virus can be in both directions. The virus survives as 
long as the host survives so the mutations can also push the virus to be less aggressive 
so that virus has a host to survive in.  
 
Apoptotic cells, IFN-α and proteasome inhibitors all have a possibility to be used in 
therapeutic and/or prophylactic interventions but the key is to identify the site of 
administration and the time of administration of these agents and also to be used in 
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